Compare G & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | IRTC |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.8B |
| IPO Year | 2007 | 2016 |
| Metric | G | IRTC |
|---|---|---|
| Price | $47.40 | $171.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $50.33 | ★ $203.93 |
| AVG Volume (30 Days) | ★ 1.9M | 479.0K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.10 | N/A |
| Revenue | ★ $5,009,342,000.00 | $702,573,000.00 |
| Revenue This Year | $8.45 | $27.20 |
| Revenue Next Year | $6.91 | $16.89 |
| P/E Ratio | $15.41 | ★ N/A |
| Revenue Growth | 7.39 | ★ 25.45 |
| 52 Week Low | $37.49 | $84.17 |
| 52 Week High | $56.76 | $212.00 |
| Indicator | G | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 70.02 | 43.54 |
| Support Level | $45.24 | $167.07 |
| Resistance Level | $46.65 | $187.98 |
| Average True Range (ATR) | 0.84 | 6.26 |
| MACD | 0.15 | -1.24 |
| Stochastic Oscillator | 87.32 | 20.77 |
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.